Published in Antimicrob Agents Chemother on October 01, 1997
Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrob Agents Chemother (1999) 7.94
Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network. J Clin Microbiol (2001) 6.66
Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother (2001) 5.23
Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrob Agents Chemother (2000) 4.31
Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae. Antimicrob Agents Chemother (2002) 3.25
Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America. Antimicrob Agents Chemother (2000) 3.00
Erythromycin resistance genes in group A streptococci in Finland. The Finnish Study Group for Antimicrobial Resistance. Antimicrob Agents Chemother (1999) 2.73
Different erythromycin resistance mechanisms in group C and group G streptococci. Antimicrob Agents Chemother (1998) 2.33
Molecular detection of antimicrobial resistance. Clin Microbiol Rev (2001) 2.31
Macrolide efflux genes mef(A) and mef(E) are carried by different genetic elements in Streptococcus pneumoniae. J Clin Microbiol (2002) 2.23
Mutation in 23S rRNA responsible for resistance to 16-membered macrolides and streptogramins in Streptococcus pneumoniae. Antimicrob Agents Chemother (2001) 2.22
Characterization of a genetic element carrying the macrolide efflux gene mef(A) in Streptococcus pneumoniae. Antimicrob Agents Chemother (2000) 2.21
Resistance to macrolides and related antibiotics in Streptococcus pneumoniae. Antimicrob Agents Chemother (2002) 2.17
Genetic elements responsible for erythromycin resistance in streptococci. Antimicrob Agents Chemother (2008) 1.79
Characterization of a Bacteroides mobilizable transposon, NBU2, which carries a functional lincomycin resistance gene. J Bacteriol (2000) 1.76
In vitro selection of resistance to four beta-lactams and azithromycin in Streptococcus pneumoniae. Antimicrob Agents Chemother (1998) 1.75
Patterns of macrolide resistance determinants among community-acquired Streptococcus pneumoniae isolates over a 5-year period of decreased macrolide susceptibility rates. Antimicrob Agents Chemother (1999) 1.75
Molecular epidemiology of erythromycin resistance in Streptococcus pneumoniae isolates from blood and noninvasive sites. J Clin Microbiol (2002) 1.71
The mef(E)-carrying genetic element (mega) of Streptococcus pneumoniae: insertion sites and association with other genetic elements. Antimicrob Agents Chemother (2006) 1.64
Presence of mefA and mefE genes in Streptococcus agalactiae. Antimicrob Agents Chemother (1999) 1.64
Serotype 19f multiresistant pneumococcal clone harboring two erythromycin resistance determinants (erm(B) and mef(A)) in South Africa. Antimicrob Agents Chemother (2001) 1.60
Phenotypes and genotypes of erythromycin-resistant pneumococci in Italy. J Clin Microbiol (2003) 1.53
Identification of an erm(A) erythromycin resistance methylase gene in Streptococcus pneumoniae isolated in Greece. Antimicrob Agents Chemother (2001) 1.50
Macrolide resistance genes in Enterococcus spp. Antimicrob Agents Chemother (2000) 1.48
Studies of the novel ketolide ABT-773: transport, binding to ribosomes, and inhibition of protein synthesis in Streptococcus pneumoniae. Antimicrob Agents Chemother (2000) 1.47
Changes in serotypes and antimicrobial susceptibility of invasive Streptococcus pneumoniae strains in Cleveland: a quarter century of experience. J Clin Microbiol (2008) 1.45
Molecular epidemiology of multiresistant Streptococcus pneumoniae with both erm(B)- and mef(A)-mediated macrolide resistance. J Clin Microbiol (2004) 1.43
Molecular characterization of pneumococci with efflux-mediated erythromycin resistance and identification of a novel mef gene subclass, mef(I). Antimicrob Agents Chemother (2005) 1.41
Differentiation of resistance phenotypes among erythromycin-resistant Pneumococci. J Clin Microbiol (2001) 1.40
A new ketolide, HMR 3004, active against streptococci inducibly resistant to erythromycin. Antimicrob Agents Chemother (1998) 1.38
Mechanisms of macrolide resistance in clinical pneumococcal isolates in France. Antimicrob Agents Chemother (2001) 1.38
Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003. Antimicrob Agents Chemother (2005) 1.35
Macrolide-resistant Streptococcus pneumoniae and Streptococcus pyogenes in the pediatric population in Germany during 2000-2001. Antimicrob Agents Chemother (2003) 1.34
Identification of the conjugative mef gene in clinical Acinetobacter junii and Neisseria gonorrhoeae isolates. Antimicrob Agents Chemother (2000) 1.29
Use of clindamycin disks To detect macrolide resistance mediated by ermB and mefE in Streptococcus pneumoniae isolates from adults and children. J Clin Microbiol (2000) 1.29
Characterization and prevalence of MefA, MefE, and the associated msr(D) gene in Streptococcus pneumoniae clinical isolates. J Clin Microbiol (2004) 1.27
Ribosomal mutations conferring resistance to macrolides in Streptococcus pneumoniae clinical strains isolated in Germany. Antimicrob Agents Chemother (2003) 1.24
A novel multiresistant Streptococcus pneumoniae serogroup 19 clone from Washington State identified by pulsed-field gel electrophoresis and restriction fragment length patterns. J Clin Microbiol (2000) 1.24
Phenotypic and molecular characterization of tetracycline- and erythromycin-resistant strains of Streptococcus pneumoniae. Antimicrob Agents Chemother (2003) 1.23
Macrolide efflux in Streptococcus pneumoniae is mediated by a dual efflux pump (mel and mef) and is erythromycin inducible. Antimicrob Agents Chemother (2005) 1.22
Simultaneous detection of nine antibiotic resistance-related genes in Streptococcus agalactiae using multiplex PCR and reverse line blot hybridization assay. Antimicrob Agents Chemother (2006) 1.20
High prevalence of inducible erythromycin resistance among Streptococcus bovis isolates in Taiwan. Antimicrob Agents Chemother (2001) 1.19
Emergence of the M phenotype of erythromycin-resistant pneumococci in South Africa. Emerg Infect Dis (1998) 1.17
Incidence of mefA and mefE genes in viridans group streptococci. Antimicrob Agents Chemother (1999) 1.13
Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients with respiratory tract infections in Germany from 1998 to 1999: results of a national surveillance study. J Clin Microbiol (2001) 1.11
Macrolide resistance in Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother (2001) 1.10
Molecular basis of resistance to macrolides and other antibiotics in commensal viridans group streptococci and Gemella spp. and transfer of resistance genes to Streptococcus pneumoniae. Antimicrob Agents Chemother (2004) 1.09
Composite structure of Streptococcus pneumoniae containing the erythromycin efflux resistance gene mefI and the chloramphenicol resistance gene catQ. Antimicrob Agents Chemother (2007) 1.08
Limiting the spread of resistant pneumococci: biological and epidemiologic evidence for the effectiveness of alternative interventions. Clin Microbiol Rev (2000) 1.07
Efflux-mediated resistance to fluoroquinolones in gram-positive bacteria and the mycobacteria. Antimicrob Agents Chemother (2000) 1.07
Molecular detection of the macrolide efflux gene: to discriminate or not to discriminate between mef(A) and mef(E). Antimicrob Agents Chemother (2005) 1.05
Macrolide-resistant Streptococcus pyogenes in Norway: population structure and resistance determinants. Antimicrob Agents Chemother (2006) 1.04
Characterization of ermB gene transposition by Tn1545 and Tn917 in macrolide-resistant Streptococcus pneumoniae isolates. J Clin Microbiol (2005) 1.03
Erythromycin resistance and genetic elements carrying macrolide efflux genes in Streptococcus agalactiae. Antimicrob Agents Chemother (2005) 1.03
Activity of HMR 3647 compared to those of five agents against Haemophilus influenzae and moraxella catarrhalis by MIC determination and time-kill assay. Antimicrob Agents Chemother (1998) 1.02
Evidence of antimicrobial resistance-conferring genetic elements among pneumococci isolated prior to 1974. BMC Genomics (2013) 1.01
In vitro activity of tebipenem, a new oral carbapenem antibiotic, against penicillin-nonsusceptible Streptococcus pneumoniae. Antimicrob Agents Chemother (2005) 0.99
Multidrug efflux pumps from Enterobacteriaceae, Vibrio cholerae and Staphylococcus aureus bacterial food pathogens. Int J Environ Res Public Health (2015) 0.96
Human antimicrobial peptide LL-37 induces MefE/Mel-mediated macrolide resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother (2010) 0.94
Prevalence and molecular genetics of macrolide resistance among Streptococcus pneumoniae isolates collected in Finland in 2002. Antimicrob Agents Chemother (2005) 0.93
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. Antimicrob Agents Chemother (2008) 0.93
Activities of cethromycin and telithromycin against recent North American isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother (2004) 0.92
Acquired macrolide resistance genes in pathogenic Neisseria spp. isolated between 1940 and 1987. Antimicrob Agents Chemother (2003) 0.92
Expression of the mef(E) gene encoding the macrolide efflux pump protein increases in Streptococcus pneumoniae with increasing resistance to macrolides. Antimicrob Agents Chemother (2005) 0.92
Mdt(A), a new efflux protein conferring multiple antibiotic resistance in Lactococcus lactis and Escherichia coli. Antimicrob Agents Chemother (2001) 0.92
Relationship between the original multiply resistant South African isolates of Streptococcus pneumoniae from 1977 to 1978 and contemporary international resistant clones. J Clin Microbiol (2005) 0.90
Molecular epidemiology of macrolide-resistant isolates of Streptococcus pneumoniae collected from blood and respiratory specimens in Norway. J Clin Microbiol (2005) 0.90
The macrolide efflux genetic assembly of Streptococcus pneumoniae is present in erythromycin-resistant Streptococcus salivarius. Antimicrob Agents Chemother (2002) 0.89
Antimicrobial resistance of invasive pneumococci in Finland in 1999-2000. Antimicrob Agents Chemother (2003) 0.89
Molecular epidemiology and prevalence of macrolide efflux genes mef(A) and mef(E) in Streptococcus pneumoniae obtained in Canada from 1997 to 2002. Antimicrob Agents Chemother (2005) 0.89
Comparative genomics study of multi-drug-resistance mechanisms in the antibiotic-resistant Streptococcus suis R61 strain. PLoS One (2011) 0.87
Incidence survey of acute otitis media in children in Sado Island, Japan--Sado Otitis Media Study (SADOMS). PLoS One (2013) 0.87
Influence of macrolide susceptibility on efficacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection model. Antimicrob Agents Chemother (2003) 0.86
Macrolide resistance gene mreA of Streptococcus agalactiae encodes a flavokinase. Antimicrob Agents Chemother (2001) 0.85
Prevalence of macrolide resistance genes in clinical isolates of the Streptococcus anginosus ("S. milleri") group. Antimicrob Agents Chemother (2001) 0.85
Characterization of macrolide efflux pump mef subclasses detected in clinical isolates of Streptococcus pyogenes isolated between 1999 and 2005. Antimicrob Agents Chemother (2009) 0.84
Susceptibilities of oral and nasal isolates of Streptococcus mitis and Streptococcus oralis to macrolides and PCR detection of resistance genes. Antimicrob Agents Chemother (2000) 0.84
Three new macrolide efflux (mef) gene variants in Streptococcus agalactiae. J Clin Microbiol (2007) 0.83
Modulation of Bacterial Multidrug Resistance Efflux Pumps of the Major Facilitator Superfamily. Int J Bacteriol (2015) 0.83
Molecular resistance mechanisms of macrolide-resistant invasive Streptococcus pneumoniae isolates from Alaska, 1986 to 2010. Antimicrob Agents Chemother (2013) 0.82
Functionally cloned pdrM from Streptococcus pneumoniae encodes a Na(+) coupled multidrug efflux pump. PLoS One (2013) 0.82
Molecular epidemiology of serotype 19A Streptococcus pneumoniae among invasive isolates from Alaska, 1986-2010. Int J Circumpolar Health (2013) 0.81
Induction of efflux-mediated macrolide resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother (2011) 0.81
Macrolide resistance determinants among Streptococcus pneumoniae isolates from carriers in Central Greece. BMC Infect Dis (2012) 0.81
Rapid identification of penicillin and macrolide resistance genes and simultaneous quantification of Streptococcus pneumoniae in purulent sputum samples by use of a novel real-time multiplex PCR assay. J Clin Microbiol (2008) 0.79
The controversial nature of the Weissella genus: technological and functional aspects versus whole genome analysis-based pathogenic potential for their application in food and health. Front Microbiol (2015) 0.78
High prevalence of the ermB gene among erythromycin-resistant streptococcus pneumoniae isolates in Germany during the winter of 2000-2001 and in vitro activity of telithromycin. Antimicrob Agents Chemother (2004) 0.77
Prevalence and mechanism of resistance to antimicrobial agents in group G streptococcal isolates from China. Antimicrob Agents Chemother (2010) 0.77
Macrolide Resistance in Streptococcus pneumoniae. Front Cell Infect Microbiol (2016) 0.75
ICESpy009, a Conjugative Genetic Element Carrying mef(E) in Streptococcus pyogenes. Antimicrob Agents Chemother (2016) 0.75
Genetic basis of the association of resistance genes mef(I) (macrolides) and catQ (chloramphenicol) in streptococci. Front Microbiol (2015) 0.75
Construction and characterization of amplifiable multicopy DNA cloning vehicles derived from the P15A cryptic miniplasmid. J Bacteriol (1978) 75.38
Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis (1992) 11.24
Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science (1994) 11.18
Detection of erythromycin-resistant determinants by PCR. Antimicrob Agents Chemother (1996) 10.56
Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother (1996) 8.65
An unmodified heptadecapeptide pheromone induces competence for genetic transformation in Streptococcus pneumoniae. Proc Natl Acad Sci U S A (1995) 7.29
Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. Antimicrob Agents Chemother (1991) 7.18
Emergence of drug-resistant pneumococcal infections in the United States. JAMA (1994) 6.29
Multidrug resistance pumps in bacteria: variations on a theme. Trends Biochem Sci (1994) 5.21
Molecular cloning and functional analysis of a novel macrolide-resistance determinant, mefA, from Streptococcus pyogenes. Mol Microbiol (1996) 4.86
Three different phenotypes of erythromycin-resistant Streptococcus pyogenes in Finland. J Antimicrob Chemother (1993) 4.83
Resistance to erythromycin in group A streptococci. N Engl J Med (1992) 4.42
Inducible erythromycin resistance in staphylococci is encoded by a member of the ATP-binding transport super-gene family. Mol Microbiol (1990) 4.03
Nucleotide sequence of the erythromycin resistance gene of the conjugative transposon Tn1545. Nucleic Acids Res (1990) 3.74
Construction and evaluation of new drug-resistance cassettes for gene disruption mutagenesis in Streptococcus pneumoniae, using an ami test platform. Gene (1995) 3.63
Novel mechanism of macrolide resistance in Streptococcus pneumoniae. Diagn Microbiol Infect Dis (1996) 3.29
Distribution of erythromycin esterase and rRNA methylase genes in members of the family Enterobacteriaceae highly resistant to erythromycin. Antimicrob Agents Chemother (1987) 2.80
Characterisation and molecular cloning of the novel macrolide-streptogramin B resistance determinant from Staphylococcus epidermidis. J Antimicrob Chemother (1989) 2.62
Variation in erythromycin and clindamycin susceptibilities of Streptococcus pneumoniae by four test methods. Antimicrob Agents Chemother (1997) 2.17
Activity of oral antibiotics in middle ear and sinus infections caused by penicillin-resistant Streptococcus pneumoniae: implications for treatment. Pediatr Infect Dis J (1994) 2.15
Efficient integration of artificial transposons into plasmid targets in vitro: a useful tool for DNA mapping, sequencing and genetic analysis. Nucleic Acids Res (1994) 1.85
The emergence of erythromycin resistance in Streptococcus pyogenes in Fremantle, Western Australia. Med J Aust (1989) 1.79
Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-AZA-9a-homoerythromycin A derivatives; a new class of macrolide antibiotics, the azalides. J Antibiot (Tokyo) (1988) 1.78
Identification of a chromosomally encoded ABC-transport system with which the staphylococcal erythromycin exporter MsrA may interact. Gene (1995) 1.57
Resistance to penicillin and non-beta-lactam antibiotics of Streptococcus pneumoniae at a children's hospital. Pediatr Infect Dis J (1994) 1.53
Cloning and sequencing of a plasmid-mediated erythromycin resistance determinant from Staphylococcus xylosus. FEMS Microbiol Lett (1992) 1.50
Rapid increase of resistance to erythromycin and clindamycin in Streptococcus pyogenes in Italy, 1993-1995. The Italian Surveillance Group for Antimicrobial Resistance. Emerg Infect Dis (1997) 1.49
Erythromycin-resistant Streptococcus pyogenes. J Antimicrob Chemother (1990) 1.49
A community outbreak of group A beta haemolytic streptococci with transferable resistance to erythromycin. Epidemiol Infect (1989) 1.42
Emergence of resistant Streptococcus pneumoniae: a problem in pediatrics. Pediatr Infect Dis J (1995) 1.42
Antibiotic resistance patterns of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a prospective study in Murcia, Spain, 1983-1992. Chemotherapy (1994) 0.99
Involvement of chemokine receptors in breast cancer metastasis. Nature (2001) 26.07
Detection of erythromycin-resistant determinants by PCR. Antimicrob Agents Chemother (1996) 10.56
Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother (1996) 8.65
Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrob Agents Chemother (1999) 7.94
Arrhythmogenesis and contractile dysfunction in heart failure: Roles of sodium-calcium exchange, inward rectifier potassium current, and residual beta-adrenergic responsiveness. Circ Res (2001) 5.08
Molecular cloning and functional analysis of a novel macrolide-resistance determinant, mefA, from Streptococcus pyogenes. Mol Microbiol (1996) 4.86
Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrob Agents Chemother (2000) 4.31
Fractional SR Ca release is regulated by trigger Ca and SR Ca content in cardiac myocytes. Am J Physiol (1995) 4.15
Upregulation of Na(+)/Ca(2+) exchanger expression and function in an arrhythmogenic rabbit model of heart failure. Circ Res (1999) 3.35
Conversion of diploidy to haploidy. Nature (2000) 3.28
Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America. Antimicrob Agents Chemother (2000) 3.00
Interfacial catalysis: the mechanism of phospholipase A2. Science (1990) 2.84
Dentinogenesis imperfecta 1 with or without progressive hearing loss is associated with distinct mutations in DSPP. Nat Genet (2001) 2.75
Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology (2000) 2.64
Vertebrate slit, a secreted ligand for the transmembrane protein roundabout, is a repellent for olfactory bulb axons. Cell (1999) 2.35
Shwachman's syndrome. A review of 21 cases. Arch Dis Child (1980) 2.32
Stimulation of type I collagen transcription in human skin fibroblasts by TGF-beta: involvement of Smad 3. J Invest Dermatol (1999) 2.20
PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. J Control Release (2001) 2.15
Clinical strain of Staphylococcus aureus inactivates and causes efflux of macrolides. Antimicrob Agents Chemother (1996) 1.88
Occupational exposure to bisphenol-A (BPA) and the risk of self-reported male sexual dysfunction. Hum Reprod (2009) 1.87
Insoluble glucan synthesis by Streptococcus mutans serotype c strains. Infect Immun (1983) 1.65
1,25-Dihydroxyvitamin D3 targeting of NF-kappaB suppresses high glucose-induced MCP-1 expression in mesangial cells. Kidney Int (2007) 1.64
Shanghai premarital adolescent use of contraceptive methods and analysis of influencing factors. Chin J Popul Sci (1997) 1.64
Vitamin A for preventing acute lower respiratory tract infections in children up to seven years of age. Cochrane Database Syst Rev (2008) 1.60
Cloning and characterization of a novel macrolide efflux gene, mreA, from Streptococcus agalactiae. Antimicrob Agents Chemother (1997) 1.59
Antagonistic regulation of type I collagen gene expression by interferon-gamma and transforming growth factor-beta. Integration at the level of p300/CBP transcriptional coactivators. J Biol Chem (2000) 1.55
Ca(2+) influx through Ca(2+) channels in rabbit ventricular myocytes during action potential clamp: influence of temperature. Circ Res (1999) 1.52
Another Colicin V phenotype: in vitro adhesion of Escherichia coli to mouse intestinal epithelium. Infect Immun (1981) 1.51
Type I error in sample size re-estimations based on observed treatment difference. Stat Med (2001) 1.50
Identification of an erm(A) erythromycin resistance methylase gene in Streptococcus pneumoniae isolated in Greece. Antimicrob Agents Chemother (2001) 1.50
Os odontoideum: etiology, diagnosis, and management. Surg Neurol (2000) 1.48
A comparison of four commercial systems used to measure whole-body electrical impedance. Physiol Meas (1993) 1.42
Generalized anxiety disorder vs. panic disorder. Distinguishing characteristics and patterns of comorbidity. J Nerv Ment Dis (1992) 1.41
Ultrasonographic evaluation of diaphragmatic motion. J Ultrasound Med (2001) 1.39
Interaction of smad3 with a proximal smad-binding element of the human alpha2(I) procollagen gene promoter required for transcriptional activation by TGF-beta. J Cell Physiol (2000) 1.36
Cytoplasmic trafficking of the canine parvovirus capsid and its role in infection and nuclear transport. J Virol (2000) 1.34
Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutations. Neurology (2007) 1.33
Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection. Antimicrob Agents Chemother (1996) 1.25
Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther (1999) 1.22
Mechanistic studies on class I polyhydroxybutyrate (PHB) synthase from Ralstonia eutropha: class I and III synthases share a similar catalytic mechanism. Biochemistry (2001) 1.21
Smad-dependent stimulation of type I collagen gene expression in human skin fibroblasts by TGF-beta involves functional cooperation with p300/CBP transcriptional coactivators. Oncogene (2000) 1.19
Value of bed rest in patients with rheumatoid arthritis. N Engl J Med (1971) 1.19
Semi-automated color segmentation of anatomical tissue. Comput Med Imaging Graph (2000) 1.18
PTEN deletion prevents ischemic brain injury by activating the mTOR signaling pathway. Biochem Biophys Res Commun (2010) 1.17
Mapping ligand binding domains in chimeric fibroblast growth factor receptor molecules. Multiple regions determine ligand binding specificity. J Biol Chem (1999) 1.14
Nonstructural protein-2 and the replication of canine parvovirus. Virology (1998) 1.13
A new antibiotic CJ-17,665 from Aspergillus ochraceus. J Antibiot (Tokyo) (2001) 1.13
The N-terminal domain of p73 interacts with the CH1 domain of p300/CREB binding protein and mediates transcriptional activation and apoptosis. Mol Cell Biol (2000) 1.12
Cloning and functional characterization of an NAD(+)-dependent DNA ligase from Staphylococcus aureus. J Bacteriol (2001) 1.11
Identification of distinct subpopulations of intercalated cells in the mouse collecting duct. J Am Soc Nephrol (1996) 1.11
The dying role: its relevance to improved patient care. Psychiatry (1977) 1.09
Macrolide resistance from the ribosome perspective. Curr Drug Targets Infect Disord (2004) 1.08
Effect of the mi allele on mast cells, basophils, natural killer cells, and osteoclasts in C57Bl/6J mice. J Cell Physiol (1987) 1.05
The prognosis of anxiety neurosis. Arch Gen Psychiatry (1980) 1.04
Cryphonectria hypovirus 3, a virus species in the family hypoviridae with a single open reading frame. Virology (1999) 1.04
Radiculopathy after laminectomy for cervical compression myelopathy. J Bone Joint Surg Br (1998) 1.04
Secondary depression in anxiety neurosis. J Nerv Ment Dis (1978) 1.02
Downregulation of microRNA-142 by proto-oncogene LMO2 and its co-factors. Leukemia (2007) 1.01
Escherichia coli outer membrane protein K is a porin. J Bacteriol (1983) 1.01
Cardiac myocyte volume, Ca2+ fluxes, and sarcoplasmic reticulum loading in pressure-overload hypertrophy. Am J Physiol (1997) 1.00
Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone (1996) 1.00
The familial prevalence of anxiety neurosis. Arch Gen Psychiatry (1978) 0.97
Direct repair of defect in lumbar spondylolysis and mild isthmic spondylolisthesis by bone grafting, with or without facet joint fusion. Eur Spine J (2001) 0.97
Teacher stress: prevalence, sources, and symptoms. Br J Educ Psychol (1978) 0.97
The use of a zero-profile device compared with an anterior plate and cage in the treatment of patients with symptomatic cervical spondylosis: A preliminary clinical investigation. Bone Joint J (2013) 0.97
Regulation of the cloned L-type cardiac calcium channel by cyclic-AMP-dependent protein kinase. FEBS Lett (1994) 0.97
Excess mortality in panic disorder. A comparison with primary unipolar depression. Arch Gen Psychiatry (1982) 0.96
Competitive inhibition of phospholipase A2 in vesicles. Biochemistry (1989) 0.96
Analysis of surface deposits on intrauterine contraceptive devices. Adv Contracept (1986) 0.95
Interaction of Streptococcus mutans glucosyltransferases with teichoic acids. Infect Immun (1980) 0.95
Hypophosphatasia. Review of 24 cases. Pediatr Radiol (1976) 0.95
Propranolol in chronic anxiety disorders. A controlled study. Arch Gen Psychiatry (1980) 0.94
Inhibition of interleukin-1 beta production by SKF86002: evidence of two sites of in vitro activity and of a time and system dependence. Mol Pharmacol (1995) 0.94
In vitro antibacterial activity of NB-003 against Propionibacterium acnes. Antimicrob Agents Chemother (2011) 0.94
[Fibrodysplasia ossificans progressiva]. Ann Radiol (Paris) (1979) 0.93
Surgical treatment of nonunited fractures of the odontoid process, with special reference to occipitocervical fusion for unreducible atlantoaxial subluxation or instability. Eur Spine J (2000) 0.93
Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial. Clin Ther (1999) 0.92
DTI values in key white matter tracts from infancy through adolescence. AJNR Am J Neuroradiol (2013) 0.91
Real-time protein biosensor arrays based on surface plasmon resonance differential phase imaging. Biosens Bioelectron (2008) 0.91
Structure activity studies of the melanocortin antagonist SHU9119 modified at the 6, 7, 8, and 9 positions. Peptides (2000) 0.90
Appetitive behavior, compulsivity, and neurochemistry in Prader-Willi syndrome. Ment Retard Dev Disabil Res Rev (2000) 0.90
Duplex ultrasound assessment of femoral venous flow during laparoscopic and open gastric bypass. Surg Endosc (2002) 0.90
Traumatically intruded permanent incisors: a study of treatment and outcome. Br Dent J (1991) 0.89
Induction of TNF alpha and TNF beta gene expression in rat cardiac transplants during allograft rejection. Transplantation (1993) 0.89
Discovery of a novel series of potent and selective substrate-based inhibitors of p60c-src protein tyrosine kinase: conformational and topographical constraints in peptide design. J Med Chem (1998) 0.89
Functional visual loss: II. Psychiatric aspects in 42 patients followed for 4 years. Psychol Med (1983) 0.89
Rap1b is critical for glycoprotein VI-mediated but not ADP receptor-mediated alpha2beta1 activation. J Thromb Haemost (2009) 0.88
Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment. Calcif Tissue Int (1998) 0.88
Evidence for separate control of slow version and vergence eye movements: support for Hering's Law. Vision Res (1998) 0.87
Potent and selective inhibitors of leukotriene A4 hydrolase: effects on purified enzyme and human polymorphonuclear leukocytes. J Pharmacol Exp Ther (1995) 0.87
Satellite and defective RNAs of Cryphonectria hypovirus 3-grand haven 2, a virus species in the family Hypoviridae with a single open reading frame. Virology (2000) 0.87
Assessment of equivalence on multiple endpoints. Stat Med (2001) 0.87
Autoradiographic analysis of cell proliferation and protein synthesis in the pulmonary trunk of rats during the early development of hypoxia-induced pulmonary hypertension. Blood Vessels (1984) 0.86
Immunological and molecular characterization of Helicobacter felis urease. Infect Immun (1994) 0.86